Mark Pruzanski - 28 May 2021 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC.

Role
Director
Signature
/s/ Mary J. Grendell, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
28 May 2021
Net transactions value
+$38,598
Form type
4
Filing time
02 Jun 2021, 19:00:43 UTC
Previous filing
28 May 2021
Next filing
01 Jul 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICPT Common Stock Award $102,075 +6,138 +1% $16.63 608,787 28 May 2021 Direct F1, F3
transaction ICPT Common Stock Tax liability $63,477 -3,817 -0.63% $16.63 604,970 28 May 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.
F2 Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.
F3 Includes 100,000 shares previously held in a grantor retained annuity trust.